BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Oct. 24, 2007
View Archived Issues
BKCa channel inhibition attenuates NO-induced dural and pial vasodilation in rats
Read More
Newly formed Proaegis Biosciences to develop drugs for ARDS and UC
Read More
Preclinical toxicology program for DTS-108 initiated at Diatos
Read More
FDA advisory committee recommends use of phosphate binders for hyperphosphatemia treatment
Read More
EMEA grants orphan medicinal product designation to picoplatin for SCLC
Read More
Phase III trial with Prochymal as first-line treatment for acute GVHD begins
Read More
bioMerieux receives FDA clearance for sepsis biomarker assay
Read More
Second phase II trial of ADL-5859 initiated for treatment of pain
Read More
Lilly and MacroGenics to develop teplizumab for autoimmune diseases
Read More
Phase IIa clinical study of MediciNova's MN-305 fails to achieve statistical significance
Read More
Complete phase Ib trial of brostallicin combination therapy in advanced solid tumors begins
Read More
Analysis reveals safe metabolic profile of bifeprunox
Read More
Aripiprazole effective as acute and maintenance therapy for bipolar disorder
Read More
RGH-188 pharmacokinetics, dopamine receptor occupancy studied in volunteers
Read More
LX-1031 well tolerated in early studies in humans
Read More
Novel agents for respiratory and allergic disorders disclosed in recent patent literature
Read More
Update on phase II and III studies of thrombin receptor antagonist
Read More
New treatment options for neurological disorders reported in recent patent literature
Read More
New calcium-activated potassium channel blockers emerge from Merck & Co. R&D
Read More
ASIC1a channels, key mediators of inflammatory pain hypersensitivity
Read More
GlaxoSmithKline receives approval for ArranonG in T-ALL and T-LBL
Read More
Acute heart failure approved as new indication for Sigmart Injection in Japan
Read More
Medtronic's drug-eluting stent receives CE Mark
Read More
DOR BioPharma receives FDA not approvable letter for orBec in GI GVHD indication
Read More
Johnson & Johnson reports third-quarter 2007 results
Read More